Quick Answer
VYCOR MEDICAL INC reported Research And Development Expense of $10.0 thousand for the year ending 2025.
- VYCOR MEDICAL INC showed a decrease of -35.0% in Research And Development Expense from 2024 to 2025.
- This data is from VYCOR MEDICAL INC's annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2010 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $762.00 | Q1 2011: $23.9 thousand | Q2 2011: $37.5 thousand | Q3 2011: $33.6 thousand | Q1 2012: $24.7 thousand | Q2 2012: $45.9 thousand | Q3 2012: $33.7 thousand | Q1 2013: $31.4 thousand | Q2 2013: $21.3 thousand | Q1 2014: $15.4 thousand | Q2 2014: $37.4 thousand | Q3 2014: $6.9 thousand | Q1 2015: $23.2 thousand | Q2 2015: $15.7 thousand | Q3 2015: $29.3 thousand | Q1 2016: $0.00 | Q3 2016: $4.2 thousand | Q1 2021: $2.7 thousand | Q2 2021: $3.9 thousand | Q3 2021: $1.8 thousand | Q1 2023: $5.5 thousand | Q2 2023: $7.6 thousand | Q3 2023: $7.3 thousand | Q2 2024: $2.3 thousand | Q3 2024: $6.4 thousand | Q1 2025: $5.8 thousand | Q2 2025: $4.2 thousand.
- Over the full 12 years of available data (2010 to 2025), VYCOR MEDICAL INC's Research And Development Expense has declined by 34.5%.
- Historical annual values: Fiscal year 2025: $10.0 thousand | Fiscal year 2024: $15.3 thousand | Fiscal year 2023: $22.6 thousand | Fiscal year 2021: $15.2 thousand | Fiscal year 2017: $3.0 thousand | Fiscal year 2016: $4.7 thousand | Fiscal year 2015: $71.5 thousand | Fiscal year 2014: $69.1 thousand | Fiscal year 2013: $53.5 thousand | Fiscal year 2012: $126.0 thousand | Fiscal year 2011: $115.7 thousand | Fiscal year 2010: $15.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: